GlobeNewsWire
19 Mar 2026, 14:40 UTC · 32w ago
Verdict
Headline leans bearish. We score RARE −1.00 across two claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
2 claims · scored −1 bearish … +1 bullish
Ultragenyx's Phase III ORBIT study failed to achieve a statistically significant reduction in annualized fracture rate for its Osteogenesis Imperfecta drug candidate.
More negative than 99% of claims this week
A class action lawsuit alleges Ultragenyx made materially false and misleading statements by giving investors a falsely optimistic impression of the drug's effects prior to the Phase III failure.
Continue reading
5 related stories
More negative than 98% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
More negative than 95% of claims this week
Which stocks this story touches
More negative than 98% of ticker scores this week
The company is facing a securities fraud class action lawsuit following a failed Phase III clinical study.
More negative than 81% of ticker scores this week
The company is mentioned as the subject of a fraud investigation.
More negative than 81% of ticker scores this week
The company is mentioned as the subject of a fraud investigation.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
2h ago
−21.3%
Price agrees with the score
$16.10 vs $20.46 close before publication (Mar 18) · not market-adjusted
RARE chart →
